Home Tags ASCO

Tag: ASCO

General views from the 2019 Annual Meeting of the American Society (ASCO), held May 31 - June 4, 2019. Courtesy © ASCO/Phil McCarten 2019.

RC48-ADC Demonstrates Clinically Meaningful Results in HER2+ Metastatic and Unresectable Urothelial...

Clinically meaningful topline results for a Phase II clinical trial of RC48-ADC were presented during the annual meeting of the American Society of Clinical...

Mersana Presents Interim Phase 1 Data for XMT-1536 at the 2019...

Mersana Therapeutics, a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates or ADCs targeting cancers in areas of high...

ASCO 2019 ADC Presentation Guide

We have created the following guide to all presentations related to ADCs for the upcoming ASCO Annual Meeting 2019 taking place at the McCormick...
Featured Image: General views at the American Society for Clinical Oncology (ASCO) annual meeting. Courtesy: © ASCO/Max Gersh 2015. Used with permission.

Phase I Data for SAR408701 Supports Further Development in Lung Cancer

During the upcoming annual meeting American Society of Clinical Oncology (ASCO) in June 2019, Sanofi's oncology franchise will present a renewed strategy to address...

Polatuzumab Vedotin Demonstrates Clinical Efficacy Across a Range of Diffuse Large...

Polatuzumab vedotin (DCDS4501A), a novel, targeted anti-cancer agent being developed by Genentech/Roche, is a first-in-class anti-CD79b antibody-drug conjugate or ADC currently being investigated for...

Eric Rosenthal Reports | A Personal Remembrance of Two Giants of...

James F. Holland, MD, one of the pioneers of combination chemotherapy and cancer cooperative group research, died at the age of 92 on March...

Phase I Data of Enfortumab Vedotin in Metastatic Urothelial Cancer Supports...

Updated phase I data for enfortumab vedotin, also known as ASG-22ME or ASG-22CE , studied as monotherapy treatment for metastatic urothelial cancer (mUC) were...

XMT-1522 Trial in Progress Data Presented at ASCO

Data from a trials in progress abstract presented during the 2017 annual meeting of the American Society of Clinical Oncology (ASCO) confirmed the continued...

What to Expect at ASCO 2017

This year the premier oncology event - the annual meeting of the American Society of Clinical Oncology (ASCO), is just around the corner. The...

Clinical Phase I Data for ASG-15ME and Enfortumab Vedotin (ASG-22ME) Indicates...

Clinical data for ASG-15ME and Enfortumab vedotin, also known as ASG-22ME and ASG-22M6E,  presented at the American Society of Clinical Oncology's (ASCO) 51st Annual Meeting held June...

FEATURED